Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

A recent phase III randomized trial found an investigational oral small-molecule GLP-1 receptor agonist significantly ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...

Mouse livers were engineered via a one-time genome editing to secrete a GLP-1, cutting weight gain and improving glucose ...

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Employers are grappling with the ripple effect of an increasingly popular weight loss treatment. Pharmacy benefit leaders at Holmes Murphy share what to consider when evaluating GLP-1s for your ...